Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.

Shares of ResMed Inc. RMD dropped 1.00% to $233.82 Friday, on what proved to be an all-around dismal trading session for the ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed Inc. - Depositary Receipt () (OTCPK:RSMDF ...

Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) have earned a consensus rating of “Hold” from the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst ...

The stock's fall snapped a three-day winning streak.

ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief ...

ResMed Inc. RMD has witnessed strong momentum in the past year. Shares of the company have risen 37.8% compared with 10.7% growth of the industry during the same time frame. The S&P 500 composite ...

Highlights,ResMed's stock price dips below its 200-day moving average.,The company posted strong quarterly earnings, ...